12:00 AM
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IDX184: Development discontinued

Idenix discontinued development of HCV candidates IDX184 and IDX19368 after FDA told the company the programs would remain on clinical hold. Last August, FDA placed IDX184 on partial clinical hold and IDX19368 on a full clinical hold following cardiac safety concerns with a similar nucleotide NS5B polymerase inhibitor, BMS-986094, from Bristol-Myers Squibb Co. (NYSE:BMY, New York, NY)....

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >